Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

One in Seven UK High Street Shops Adopt Cashless Payments

New survey reveals a significant shift towards cashless transactions.Highlights: One in seven UK high street shops went cashless...

Morgan Stanley to Cut 2,500 Staff Across Divisions

The bank aims to streamline operations amidst economic uncertainties.Highlights: Morgan Stanley plans to cut 2,500 jobs across various...

Lloyds to Sell Customer Data to Cut IT Costs and Strengthen Fintech Position

The bank aims to optimize operations and enhance its fintech offerings.Highlights: Lloyds is selling customer data to reduce...

Robinhood Launches $695 Annual Platinum Credit Card, Challenging Amex

The new offering aims to disrupt the premium credit card market.Highlights: Robinhood's new Platinum credit card costs $695...